iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
NCT ID: NCT06205225
Last Updated: 2026-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
360 participants
INTERVENTIONAL
2024-10-04
2028-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Can the use of consumer mHealth apps and devices (MyApps) improve heart failure self-care and reduce days lost due to cardiovascular hospitalization or death for any cause?
2. Can a program of individually tailored text messages (Text4HF) improve heart failure self-care and reduce the days lost due to cardiovascular hospitalization or death for any cause?
3. Can MyApps and Text4HF combined lead to greater improvements in heart failure self-care and days lost due to cardiovascular hospitalization or death for any cause
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patient-centered Mobile Health Intervention to Improve Self-care in Patients With Chronic Heart Failure
NCT03642275
An Innovative Mobile Health Intervention to Improve Self-care in Patients With Heart Failure
NCT04262544
Heart Failure Self-care With the Aid of a Smartphone Application
NCT03194841
The Effects of Self-monitoring With a Mobile Application in Heart Failure
NCT03149510
Trial of a Tailored Message Program to Implement CHF Guidelines
NCT00013026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To address this gap, our team developed a patient-centered HF self-care intervention (iCardia4HF) that combines the use of three consumer mobile health apps and connected health devices (MyApps) with a program of individually tailored text messages (Text4HF) targeting modifiable behavioral factors to promote HF self-care adherence and improve clinical outcomes.
This study aims to conduct a fully powered, 2x2 factorial randomized controlled trial to determine the independent and combined efficacy of the two iCardia4HF intervention components (MyApps and Text4HF) at 6 months, as well as their maintenance efficacy at 6 months post-intervention. A total of 360 patients with HF will be recruited and randomized to one of four conditions for 12 months: (1) Usual care, (2) Text4HF, (3) MyApps, or (4) MyApps\&Text4HF. Specific aims are:
Aim 1: Determine the independent and combined efficacies of MyApps and Text4HF at 6-months on the primary outcome of days lost due to cardiovascular hospitalization or death for any cause, and secondary outcomes of HF self-care and health status.
Hypothesis 1a: MyApps and Text4HF will have significant main effects on the primary outcome at 6 months.
Hypothesis 1b: MyApps and Text4HF will have significant main effects on objectively assessed measures of HF self-care adherence, self-reported HF self-care, and health status, at 6 months.
Aim 2: Determine the independent and combined maintenance efficacies of MyApps and Text4HF at 12 months (6 months post-intervention).
Hypothesis 2a: Text4HF and MyApps will have significant main effects on the primary outcome at 12 months.
Hypothesis 2b: Text4HF and MyApps will have significant main effects on objectively assessed measures of HF self-care adherence, self-reported HF self-care, and health status, at 12 months.
Aim 3: Investigate the mediating effect of intervention targets (health beliefs, HF knowledge, self-efficacy), and moderating effect of multi-level determinants of HF self-care adherence on the efficacy of the intervention, across individual (e.g., age, race/ethnicity), illness-related (e.g., depression, comorbidities), and socioeconomic factors (e.g., insurance, income, employment, and access to care).
Impact statement: This study will provide important new knowledge that will critically shape our understanding about the potential of commercially available mHealth technologies and tailored text messages to improve HF self-care adherence and reduce hospital readmissions in patients with HF.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Enhanced usual care
Participants assigned to the usual care group will receive (1) standard care, (2) patient education about HF self-care, and (3) three connected health devices. Usual care includes follow-up appointments every 2-3 months with a multidisciplinary team at the outpatient HF clinic. Patient education includes resources about HF self-care from the American Heart Association and Heart Failure Society of America. Connected health devices include the Withings Weight Scale, Withings blood pressure monitor, and Fitbit Charge 6 activity tracker (wrist-based with heart rate sensor). Participants will receive the devices at baseline along with training by research staff on how to use the devices to perform daily self-monitoring of weight, blood pressure, and physical activity/inactivity. The Withings devices have a cellular antenna for automatic transmission of data to our study server (iCardia). Fitbit will be paired with the participant's smartphone.
Enhanced Usual Care
Participants assigned to the enhanced usual care group will receive (1) standard care, (2) patient education about HF self-care, and (3) three connected health devices (Withings weight scale and blood pressure monitor, and Fitbit activity tracker with Fitbit mobile app).
Text4HF
Participants allocated to the Text4HF group will receive the same components and devices as the usual care group (usual care, patient education, and connected health devices), plus individually tailored Text Messages targeting health beliefs, HF-knowledge, and self-efficacy about HF self-care. Participants will receive 4-6 TMs/week during the induction phase (0 to 3 months), and 2-4 TMs per week during the adoption period (3 to 6 months).Tailoring of the TMs is guided by participants' responses to validated instruments assessing intervention target variables at baseline and 3 months
Text4HF
Behavioral text messages about heart failure self-care
MyApps
In addition to usual care and patient education resources, participants in the MyApps group will receive three commercially available apps (Heart Failure Storylines, Withings Health Mate, and Fitbit), and three connected health devices (Withings Body Cardio Scale, Withings BP monitor, and Fitbit activity tracker). The apps interface with the devices via Bluetooth offering patients a comprehensive set of mHealth tools that support the core elements of HF self-care (maintenance, self-monitoring, and self-management).
MyApps
consumer mobile health apps and devices for heart failure self-care
MyApps + Text4HF
Participants in this group will receive the MyApps and Text4HF intervention components, combined.
MyApps & Text4HF
Consumer mobile health apps and devices supplemented with behavioral text messages for heart failure self-care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Text4HF
Behavioral text messages about heart failure self-care
MyApps
consumer mobile health apps and devices for heart failure self-care
MyApps & Text4HF
Consumer mobile health apps and devices supplemented with behavioral text messages for heart failure self-care
Enhanced Usual Care
Participants assigned to the enhanced usual care group will receive (1) standard care, (2) patient education about HF self-care, and (3) three connected health devices (Withings weight scale and blood pressure monitor, and Fitbit activity tracker with Fitbit mobile app).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 18 years of age
* Transthoracic Echocardiogram or Cardiac MRI performed in the last 3 years and LVEF results available
* Patient is actively treated with oral loop diuretics for chronic heart failure
* Hospitalization due to acute decompensated heart failure within 24 months before randomization and/or insufficient self-care per SCHFI assessment (score of ≤3, in at least two items of the SCHFI v7.2 maintenance, symptom monitoring, or self-care management subscale)
* Ability to speak and read English
Exclusion Criteria
* High urgent listed for heart transplantation
* Acute coronary syndrome within the last 7 days before randomization
* Revascularization and/or CRT implantation within 28 days before randomization
* Planned revascularization, transcatheter aortic valve implantation, MitraClip and/or CRT implantation within 3 months after randomization
* End-stage HF (hospice candidate)
* Discharge to a setting other than home
* Individuals who have a home nurse or are not able to take care of self (eat, dress, walk, bathe, take medications, or use the toilet)
* Chronic renal insufficiency with hemodialysis or estimated Glomerular Filtration Rate \<25 mL
* Active cancer, currently undergoing treatment (e.g. radiation immunotherapy)
* Existence of any disease reducing life expectancy to less than 1 year
* Cognitive impairment (e.g., Dementia, Parkinson disease, Alzheimer disease, MoCA\<18, impaired self-determination, lacking ability to communicate)
* Major physical impairment (e.g., inability to walk, bound on a wheelchair)
* Unwillingness to use study equipment
* Active substance abuse
* Currently pregnant, less than 3-month post-partum or pregnancy anticipated during the study
* Participation in other treatment studies or remote patient management programs
* Participation in the iCardia4H pilot trial (conducted before this study)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
University of Illinois at Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Spyros Kitsiou
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Spyros Kitsiou, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Illinois Chicago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rush University Medical Center
Chicago, Illinois, United States
University of Illinois Hospital & Health Sciences System
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-1592
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.